Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients

Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2017-09, Vol.5 (5), p.1264-1271
Hauptverfasser: Vos, Byrthe J.P.R., MD, PhD, van Anrooij, Bjorn, BSc, van Doormaal, Jasper J., MD, PhD, Dubois, Anthony E.J., MD, PhD, Oude Elberink, Joanne N.G., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1271
container_issue 5
container_start_page 1264
container_title The journal of allergy and clinical immunology in practice (Cambridge, MA)
container_volume 5
creator Vos, Byrthe J.P.R., MD, PhD
van Anrooij, Bjorn, BSc
van Doormaal, Jasper J., MD, PhD
Dubois, Anthony E.J., MD, PhD
Oude Elberink, Joanne N.G., MD, PhD
description Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P < .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L.
doi_str_mv 10.1016/j.jaip.2017.03.019
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1899116516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213219817301903</els_id><sourcerecordid>1899116516</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</originalsourceid><addsrcrecordid>eNp9Uk1v1DAUjBCIVqV_gAOyxIVLgj8SfyCEtKooFBUV0XLgZLn2CzibjVPbS9l_j6NtQeoBX2yNZ0bvvXlV9ZzghmDCXw_NYPzcUExEg1mDiXpUHVJKWE0L9vj-TZQ8qI5TGnA5kgjc4qfVAZWtUkLIw-r21GQzotVk5p-70fz2CeWAvsM4hlv0ydg1ZHSZ_fQjIT-hzyblYHc5JJ_eoIs5-zAl1IeIzhxM2ffemgVDZnLoKoLJmwKj0KNVrr_6tEZfyn-B0rPqSW_GBMd391H17fT91cnH-vziw9nJ6ry2rWS5Nsw4I6XqsO0xB9VzIB1AJ2grqJJUcutA9gY65zinlPOWO0mZIHDdgjHsqHq1951juNlCynrjky3tmQnCNmkilSKEd4QX6ssH1CFs41Sq00QxIbhqeVdYdM-yMaQUoddz9BsTd5pgvSSjB70ko5dkNGa6JFNEL-6st9cbcH8l9zkUwts9AcosfnmIOtkyJwvOR7BZu-D_7__ugdyOfiphjGvYQfrXh05UY3257MayGkSwIseM_QEzV7Qm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1937769465</pqid></control><display><type>article</type><title>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Vos, Byrthe J.P.R., MD, PhD ; van Anrooij, Bjorn, BSc ; van Doormaal, Jasper J., MD, PhD ; Dubois, Anthony E.J., MD, PhD ; Oude Elberink, Joanne N.G., MD, PhD</creator><creatorcontrib>Vos, Byrthe J.P.R., MD, PhD ; van Anrooij, Bjorn, BSc ; van Doormaal, Jasper J., MD, PhD ; Dubois, Anthony E.J., MD, PhD ; Oude Elberink, Joanne N.G., MD, PhD</creatorcontrib><description>Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P &lt; .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L.</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2017.03.019</identifier><identifier>PMID: 28499778</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Accuracy ; Adult ; Adults ; Allergens - immunology ; Allergies ; Allergy and Immunology ; Anaphylaxis ; Anaphylaxis - diagnosis ; Anaphylaxis - epidemiology ; Anaphylaxis - therapy ; Animal bites ; Animals ; Bees ; Desensitization, Immunologic - methods ; Epidemiology ; Epinephrine - therapeutic use ; Fatal Outcome ; Female ; Health risk assessment ; Humans ; Hymenoptera ; Immunoglobulin E ; Immunoglobulin E - blood ; Immunotherapy ; Indolent systemic mastocytosis ; Insect Bites and Stings - diagnosis ; Insect Bites and Stings - epidemiology ; Internal Medicine ; Male ; Mastocytosis ; Mastocytosis, Systemic - diagnosis ; Mastocytosis, Systemic - epidemiology ; Mastocytosis, Systemic - therapy ; Middle Aged ; Patients ; Risk ; Sensitivity and Specificity ; Sensitization ; Specific IgE ; Stings ; Tryptases - blood ; Urticaria Pigmentosa ; Venom ; Ves v 5 ; Wasp Venoms - immunology ; Wasps ; Yellow jacket</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-09, Vol.5 (5), p.1264-1271</ispartof><rights>American Academy of Allergy, Asthma &amp; Immunology</rights><rights>2017 American Academy of Allergy, Asthma &amp; Immunology</rights><rights>Copyright © 2017 American Academy of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</citedby><cites>FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28499778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vos, Byrthe J.P.R., MD, PhD</creatorcontrib><creatorcontrib>van Anrooij, Bjorn, BSc</creatorcontrib><creatorcontrib>van Doormaal, Jasper J., MD, PhD</creatorcontrib><creatorcontrib>Dubois, Anthony E.J., MD, PhD</creatorcontrib><creatorcontrib>Oude Elberink, Joanne N.G., MD, PhD</creatorcontrib><title>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P &lt; .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L.</description><subject>Accuracy</subject><subject>Adult</subject><subject>Adults</subject><subject>Allergens - immunology</subject><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Anaphylaxis</subject><subject>Anaphylaxis - diagnosis</subject><subject>Anaphylaxis - epidemiology</subject><subject>Anaphylaxis - therapy</subject><subject>Animal bites</subject><subject>Animals</subject><subject>Bees</subject><subject>Desensitization, Immunologic - methods</subject><subject>Epidemiology</subject><subject>Epinephrine - therapeutic use</subject><subject>Fatal Outcome</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hymenoptera</subject><subject>Immunoglobulin E</subject><subject>Immunoglobulin E - blood</subject><subject>Immunotherapy</subject><subject>Indolent systemic mastocytosis</subject><subject>Insect Bites and Stings - diagnosis</subject><subject>Insect Bites and Stings - epidemiology</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Mastocytosis</subject><subject>Mastocytosis, Systemic - diagnosis</subject><subject>Mastocytosis, Systemic - epidemiology</subject><subject>Mastocytosis, Systemic - therapy</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Risk</subject><subject>Sensitivity and Specificity</subject><subject>Sensitization</subject><subject>Specific IgE</subject><subject>Stings</subject><subject>Tryptases - blood</subject><subject>Urticaria Pigmentosa</subject><subject>Venom</subject><subject>Ves v 5</subject><subject>Wasp Venoms - immunology</subject><subject>Wasps</subject><subject>Yellow jacket</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uk1v1DAUjBCIVqV_gAOyxIVLgj8SfyCEtKooFBUV0XLgZLn2CzibjVPbS9l_j6NtQeoBX2yNZ0bvvXlV9ZzghmDCXw_NYPzcUExEg1mDiXpUHVJKWE0L9vj-TZQ8qI5TGnA5kgjc4qfVAZWtUkLIw-r21GQzotVk5p-70fz2CeWAvsM4hlv0ydg1ZHSZ_fQjIT-hzyblYHc5JJ_eoIs5-zAl1IeIzhxM2ffemgVDZnLoKoLJmwKj0KNVrr_6tEZfyn-B0rPqSW_GBMd391H17fT91cnH-vziw9nJ6ry2rWS5Nsw4I6XqsO0xB9VzIB1AJ2grqJJUcutA9gY65zinlPOWO0mZIHDdgjHsqHq1951juNlCynrjky3tmQnCNmkilSKEd4QX6ssH1CFs41Sq00QxIbhqeVdYdM-yMaQUoddz9BsTd5pgvSSjB70ko5dkNGa6JFNEL-6st9cbcH8l9zkUwts9AcosfnmIOtkyJwvOR7BZu-D_7__ugdyOfiphjGvYQfrXh05UY3257MayGkSwIseM_QEzV7Qm</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Vos, Byrthe J.P.R., MD, PhD</creator><creator>van Anrooij, Bjorn, BSc</creator><creator>van Doormaal, Jasper J., MD, PhD</creator><creator>Dubois, Anthony E.J., MD, PhD</creator><creator>Oude Elberink, Joanne N.G., MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</title><author>Vos, Byrthe J.P.R., MD, PhD ; van Anrooij, Bjorn, BSc ; van Doormaal, Jasper J., MD, PhD ; Dubois, Anthony E.J., MD, PhD ; Oude Elberink, Joanne N.G., MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-a3ada88950cf06e9f6e15ee57247298286cde8fae5dd66226646d82371eb4eaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Accuracy</topic><topic>Adult</topic><topic>Adults</topic><topic>Allergens - immunology</topic><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Anaphylaxis</topic><topic>Anaphylaxis - diagnosis</topic><topic>Anaphylaxis - epidemiology</topic><topic>Anaphylaxis - therapy</topic><topic>Animal bites</topic><topic>Animals</topic><topic>Bees</topic><topic>Desensitization, Immunologic - methods</topic><topic>Epidemiology</topic><topic>Epinephrine - therapeutic use</topic><topic>Fatal Outcome</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hymenoptera</topic><topic>Immunoglobulin E</topic><topic>Immunoglobulin E - blood</topic><topic>Immunotherapy</topic><topic>Indolent systemic mastocytosis</topic><topic>Insect Bites and Stings - diagnosis</topic><topic>Insect Bites and Stings - epidemiology</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Mastocytosis</topic><topic>Mastocytosis, Systemic - diagnosis</topic><topic>Mastocytosis, Systemic - epidemiology</topic><topic>Mastocytosis, Systemic - therapy</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Risk</topic><topic>Sensitivity and Specificity</topic><topic>Sensitization</topic><topic>Specific IgE</topic><topic>Stings</topic><topic>Tryptases - blood</topic><topic>Urticaria Pigmentosa</topic><topic>Venom</topic><topic>Ves v 5</topic><topic>Wasp Venoms - immunology</topic><topic>Wasps</topic><topic>Yellow jacket</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vos, Byrthe J.P.R., MD, PhD</creatorcontrib><creatorcontrib>van Anrooij, Bjorn, BSc</creatorcontrib><creatorcontrib>van Doormaal, Jasper J., MD, PhD</creatorcontrib><creatorcontrib>Dubois, Anthony E.J., MD, PhD</creatorcontrib><creatorcontrib>Oude Elberink, Joanne N.G., MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vos, Byrthe J.P.R., MD, PhD</au><au>van Anrooij, Bjorn, BSc</au><au>van Doormaal, Jasper J., MD, PhD</au><au>Dubois, Anthony E.J., MD, PhD</au><au>Oude Elberink, Joanne N.G., MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>5</volume><issue>5</issue><spage>1264</spage><epage>1271</epage><pages>1264-1271</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>Background Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA /L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. Objective To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. Methods All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). Results A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA /L; P &lt; .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA /L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA /L (sensitivity, 83.6%; specificity, 85.0%). Conclusions The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA /L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA /L.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28499778</pmid><doi>10.1016/j.jaip.2017.03.019</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2213-2198
ispartof The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-09, Vol.5 (5), p.1264-1271
issn 2213-2198
2213-2201
language eng
recordid cdi_proquest_miscellaneous_1899116516
source MEDLINE; Alma/SFX Local Collection
subjects Accuracy
Adult
Adults
Allergens - immunology
Allergies
Allergy and Immunology
Anaphylaxis
Anaphylaxis - diagnosis
Anaphylaxis - epidemiology
Anaphylaxis - therapy
Animal bites
Animals
Bees
Desensitization, Immunologic - methods
Epidemiology
Epinephrine - therapeutic use
Fatal Outcome
Female
Health risk assessment
Humans
Hymenoptera
Immunoglobulin E
Immunoglobulin E - blood
Immunotherapy
Indolent systemic mastocytosis
Insect Bites and Stings - diagnosis
Insect Bites and Stings - epidemiology
Internal Medicine
Male
Mastocytosis
Mastocytosis, Systemic - diagnosis
Mastocytosis, Systemic - epidemiology
Mastocytosis, Systemic - therapy
Middle Aged
Patients
Risk
Sensitivity and Specificity
Sensitization
Specific IgE
Stings
Tryptases - blood
Urticaria Pigmentosa
Venom
Ves v 5
Wasp Venoms - immunology
Wasps
Yellow jacket
title Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T02%3A43%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fatal%20Anaphylaxis%20to%20Yellow%20Jacket%20Stings%20in%20Mastocytosis:%20Options%20for%20Identification%20and%20Treatment%20of%20At-Risk%20Patients&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Vos,%20Byrthe%20J.P.R.,%20MD,%20PhD&rft.date=2017-09-01&rft.volume=5&rft.issue=5&rft.spage=1264&rft.epage=1271&rft.pages=1264-1271&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2017.03.019&rft_dat=%3Cproquest_cross%3E1899116516%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1937769465&rft_id=info:pmid/28499778&rft_els_id=S2213219817301903&rfr_iscdi=true